October 21, 2016
Eiger BioPharmaceuticals Inc. announced the first patient in the Lambda Interferon MonoTherapy in HDV clinical study has been dosed with pegylated interferon lambda-1a, a potential therapeutic for chronic hepatitis D virus infection.
Pegylated interferon lambda-1a (Eiger BioPharmaceuticals), known as lambda, is a type 3 interferon currently being tested in the clinical trial as potential monotherapy and combination regimen for individuals with chronic HDV. The Lambda Interferon MonoTherapy in HDV (LIMT HDV) trial is a 30-patient study designed to evaluate the safety, tolerability and efficacy of two dose levels of lambda after 48 weeks of treatment, per the release. Patients will receive either 120 or 180 microgram subcutaneous injections administered weekly.